Incyte

INCYTE CORP

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Xpeng g6 SUV

Equities

Large Cap

News

Movers

BEKE

FUTU

INCY

MRNA

RDDT

XPEV

Large-cap stocks worst performers last week, including BEKE, RDDT, FUTU, JHX, INCY, NUE, BAH, XPEV, MRNA, TU, WLK. Are they in your portfolio?

XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

Why It Matters

Price Target

Markets

Analyst Ratings

Trading Ideas

ALGN

GOOGL

LYFT

PENN

TSLA

Tesla To $320? Here Are 10 Top Analyst Forecasts For Tuesday

Pepsi Bets $1.95 Billion On ‘Shark Tank’-Born Soda Brand

Downgrades

PCAR

TPIC

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Incyte Corp

Press Releases

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Incyte to Present at Upcoming Investor Conferences

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Morgan Stanley

Truist Securities

Guggenheim

RBC Capital

Citigroup

Incyte Pharms

Comments

Incyte

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga